UK doctors and patients can access the TRIPP RCT, and my guess is that's where patients are being sent. I would be happy enough just to see more UK sites in the study.
When the study stops, we will see what the UK clinicians thought of Oncosil during the study and then they might recommend it to hospitals and patients for private reimbursement. If TRIPP results are positive, I think UK will start ordering.
UK NHS is a cash strapped pretty poor over bureaucratised health system.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.025(2.43%) |
Mkt cap ! $14.29M | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.05 | $1.00 | $41.05K | 40.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 1249 | 1 |
View Market Depth
| Last trade - 15.47pm 20/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |